Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Open-Label, Multicenter Study With a Safety Run-In to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of MT027 Administrated Intracerebroventricularly in Patients With Recurrent or Progressive Glioblastoma (WHO Grade 4)

NCT07386002 is registered in ClinicalTrials.gov with T-MAXIMUM Pharmaceutical Inc as lead sponsor.

NCT NCT07386002
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07386002 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Open-Label, Multicenter Study With a Safety Run-In to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of MT027 Administrated Intracerebroventricularly in Patients With Recurrent or Progressive Glioblastoma (WHO Grade 4)
Lead sponsor
T-MAXIMUM Pharmaceutical Inc
Phase
Phase 2
Overall status
Not yet recruiting
Start date
November 30, 2026
Completion date
July 31, 2029
Enrollment
40 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma idh (isocitrate dehydrogenase) wildtype